Status:
COMPLETED
Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI
Lead Sponsor:
Alexandria University
Conditions:
AKI - Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the current study is to assess the predictive value of renal cell arrest biomarkers (urinary TIMP2 and IGFBP7), renal damage biomarkers (urinary KIM-1) and microscopic examination of urinar...
Detailed Description
Acute kidney injury occurred in about 45-53% of patients with sepsis, and most septic AKI was mild or moderate AKI (KDIGO stage 1 or stage 2). However, previous study showed that up to 40% of these m...
Eligibility Criteria
Inclusion
- AKI stage 1 or 2 according to KDIGO definition.
- Sepsis is defined based on the third international consensus definitions for sepsis and septic shock (Sepsis-3) as life threatening organ dysfunction caused by a dysregulated host response to infection. At least two of systemic inflammatory response syndrome (SIRS) criteria should be present
Exclusion
- Age less than 18 years.
- Patients with pre-existing chronic kidney disease (eGFR\<60 ml/min/1.73m2).
- Previous renal replacement therapy.
- Acute kidney injury caused by permanent postrenal obstruction.
- Pregnancy.
- Hepatorenal syndrome.
- Renal transplant recipients.
- Patients for whom survival to 30 days is unlikely due to end stage disease (end stage liver or heart disease or untreatable malignancy).
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06064487
Start Date
October 1 2023
End Date
June 1 2024
Last Update
June 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Aexandria University
Alexandria, Egypt, 21526